Metin Ergül

Metin Ergül

Auto-generated profile, based on publicly available information

Metin Ergül

Kocaeli University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2024 in Renal Failure
Verified
Journal Article
Open access
AOAysegul Oruc
Aysegul Oruc
ASAbdullah Sumnu
Abdullah Sumnu
ATAydın Turkmen
Aydın Turkmen
TBTaner Basturk
Taner Basturk
ECEgemen Cebeci
Egemen Cebeci
MGMeltem Gursu
Meltem Gursu
Immunoglobulin A (IgA) nephropathy (IgAN) treatment consists of maximal supportive care and, for high-risk individuals, immunosuppressive treatment (IST). There are conflicting results regarding IST. Therefore, we aimed to investigate IST results among IgAN patients in Turkiye. The data of 1656 IgAN patients in the Primary Glomerular Diseases Study of the Turkish Society of Nephrology Glomerular Diseases Study Group were analyzed. A total of 408 primary IgAN patients treated with IST (65.4% male, mean age 38.4 ± 12.5 years, follow-up 30 (3-218) months) were included and divided into two groups according to treatment protocols (isolated corticosteroid [CS] 70.6% and combined IST 29.4%). Treatment responses, associated factors were analyzed. Remission (66.7% partial, 33.7% complete) was achieved in 74.7% of patients. Baseline systolic blood pressure, mean arterial pressure, and proteinuria levels were lower in responsives. Remission was achieved at significantly higher rates in the CS group (78% vs. 66.7%, p = 0.016). Partial remission was the prominent remission type. The remission rate was significantly higher among patients with segmental sclerosis compared to those without (60.4% vs. 49%, p = 0.047). In the multivariate analysis, MEST-C S1 (HR 1.43, 95% CI 1.08-1.89, p = 0.013), MEST-C T1 (HR 0.68, 95% CI 0.51-0.91, p = 0.008) and combined IST (HR 0.66, 95% CI 0.49-0.91, p = 0.009) were found to be significant regarding remission. CS can significantly improve remission in high-risk Turkish IgAN patients, despite the reliance on non-quantitative endpoints for favorable renal outcomes. Key predictors of remission include baseline proteinuria and specific histological markers. It is crucial to carefully weigh the risks and benefits of immunosuppressive therapy for these patients.

1 January 2022 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
MDMevlut Tamer Dincer
Mevlut Tamer Dincer
NENecmi Eren
Necmi Eren
AMAhmet Murt
Ahmet Murt
NYNuri̇yE Yildiz
Nuri̇yE Yildiz
ŞÖşeyda gül özcan
şeyda gül özcan
NSNurhan Seyahi
Nurhan Seyahi
Background/aim: Data on antibody response following COVID-19 in kidney transplant recipients is scarce. This crosssectional study aims to investigate the antibody response to COVID-19 among kidney transplant recipients. Materials and methods: We recruited 46 kidney transplant recipients with RT-PCR-confirmed COVID-19 and 45 recipients without COVID-19 history. We also constructed two control groups (COVID-19 positive and negative) from a historical cohort of healthcare workers. We used age and sex-based propensity score matching to select the eligible subjects to the control groups. We measured the SARS-CoV-2 IgG levels quantitatively using the Abbott ARCHITECT system. An antibody level above 1.4 S/C was defined as positivity. Results: Transplant recipients with COVID-19 had a higher BMI, and COVID-19 history in a household member was more common than that of the transplant recipient without COVID-19. IgG seropositivity rate (69.6% vs. 78.3%, p = 0.238) and the median IgG level (3.28 [IQR: 0.80-5.85] vs. 4.59 [IQR: 1.61-6.06], p = 0.499) were similar in COVID-19-positive transplant recipients and controls. Kidney transplant recipients who had a longer duration between RT-PCR and antibody testing had lower antibody levels (r = -0.532, p < 0.001). Conclusion: At the early post-COVID-19 period, kidney transplant recipients have a similar antibody response to controls. However, these patients' antibody levels and immunity should be closely monitored in the long term.

29 May 2021 in Kocaeli Üniversitesi Sağlık Bilimleri Dergisi
Verified
Journal Article
Closed access
İÇİsa ÇAM
İsa ÇAM
SGSamet Genez
Samet Genez
EŞErkan Şengül
Erkan Şengül
UKURAL KOC
URAL KOC
AYAhmet YALNIZ
Ahmet YALNIZ
EÇErcüment Çi̇tfçi̇
Ercüment Çi̇tfçi̇
Objective: To determine the patency rates and reasons for failure using different access routes for tunneled hemodialysis catheters. Methods: The records of patients who underwent insertion of 14 French tunnelled hemodialysis catheters were retrospectively analyzed. Catheter patency survival was demonstrated using Kaplan-Meier survival curve. Catheter failure and exchange reasons were evaluated. Results: One hundred and six patients underwent 474 catheter exchanges (mean/patient 4.47±1.62). Access was via right internal jugular vein (IJV) n=40, left IJV n=23, right femoral vein (FV) n=18, left FV n=11 and transhepatic vein n=14. The causes of catheter failure and exchange were: catheter-associated infection, catheter thrombosis, fibrin sheath and catheter tip malposition. Mean primary and cumulative catheter patency time was higher in the right IJV group (732 and 1337 days, respectively) compared with the others (p

30 June 2025 in Acta Medica Nicomedia
Verified
Journal Article
Open access
PDF file
BCBurak Can
Burak Can
SBSibel BEK
Sibel BEK
MEMetin Ergül
Metin Ergül
ABAdnan Batman
Adnan Batman
NENecmi Eren
Necmi Eren
EDErkan Dervişoğlu
Erkan Dervişoğlu
Introduction: Asymmetric dimethylarginine is a major inhibitor of nitric oxide synthesis. Erectile dysfunction and chronic kidney disease (CKD) are associated with elevated levels of asymmetric dimethylarginine. This study aimed to examine the effects of ADMA on erectile dysfunction in patients undergoing peritoneal hemodialysis. Methods: A total of 32 peritoneal, 32 hemodialysis patients, and 32 healthy male volunteers were included in the study. Serum asymmetric dimethylarginine levels were measured, and clinical and laboratory parameters were analyzed. The International Index of Erectile Function-5 was used to evaluate sexual function and the Pittsburgh Sleep Quality Index was used to evaluate sleep quality. Depressive symptoms were assessed using the Beck Depression Inventory Scale. Results: Asymmetric dimethylarginine levels differed significantly among the three groups (p

26 December 2025 in SN Comprehensive Clinical Medicine
Verified
Journal Article
Closed access
ŞAŞerife Şeyda Zengin Acemoğlu
Şerife Şeyda Zengin Acemoğlu
MEMetin Ergül
Metin Ergül
OSOmur Gokmen Sevindik
Omur Gokmen Sevindik
FDFatih Demirkan
Fatih Demirkan

23 December 2024 in Uludağ Üniversitesi Tıp Fakültesi Dergisi
Verified
Journal Article
Open access
MEMetin Ergül
Metin Ergül
ŞAŞerife Şeyda Zengin Acemoğlu
Şerife Şeyda Zengin Acemoğlu
KAKemal Aygun
Kemal Aygun
EBElif Işınsu Başoğlu
Elif Işınsu Başoğlu
OSOmur Gokmen Sevindik
Omur Gokmen Sevindik
FDFatih Demirkıran
Fatih Demirkıran
Therapeutic plasmapheresis exchange (TPE) treatment is used successfully in many neurological diseases. At our center, TPE is used in many neurological cases in addition to various other diseases. In this study, data of patients who underwent TPE between January 2010 and December 2014 were analyzed. In total, 775 sessions, 114 cycles, and 86 patients’ date were evaluated and analyzed. The median age was 49.8 years. 75 patients were followed in the neurology department and 11 patients were followed in the internal medicine intensive care unit. The most common indications for plasmapheresis were myasthenia gravis, multiple sclerosis, and polyneuropathies (respectively, %35, %21, %9.3). In TPE, hypotension developed much less in those using Fresh Frozen Plasma (FFP) as replacement fluid compared to those using albumin [respectively, 2 (%0.9); 25(%4.4)] (p